Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-10-Speech-1-232-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Pharmacovigilance (amendment of Directive 2001/83/EC) - Pharmacovigilance (amendment of Regulation (EC) No 726/2004) (debate)2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20120910.29.1-232-000"2
lpv:hasSubsequent	lp_eu:2012-09-10-Speech-1-233-0002
lpv:speaker	lp:Oreste Rossi2
lpv:spokenAs	substitute; ITRE (2012-01-19--2013-07-02)3 unknown; Lega Nord (2009-07-14--2013-03-14)3 member; ENVI (2012-01-19--2014-06-30)3 member; Delegation for relations with Iran (2012-02-15--2014-06-30)3 member; EFD (2009-07-14--2013-06-11)3
lpv:translated text	"Madam President, ladies and gentlemen, first of all, I would like to thank Ms McAvan for the work she has done, which I endorse. The entry into force of the new provisions has significantly strengthened the legal framework for the surveillance of medicinal products. The overall strategic objectives of the new regulation and the new directive are in line with the overall objectives of EU legislation in the pharmaceutical field and their aim is, above all, to provide better health protection for citizens and ensure the proper functioning of the internal market as regards medicinal products for human use. I support the proposal since I consider it vital, in order to protect patients, to strengthen pharmacovigilance systems so as to guarantee greater transparency in procedures, thereby improving the effectiveness of products. Recent cases have shown the need for a further improvement of the system. It is appropriate to continually define a medicinal product’s tolerability profile under actual conditions of use and to promote balance in the use of medicinal products among the population."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph